168 related articles for article (PubMed ID: 36549661)
21. Epstein-Barr Virus Predicts Malignancy After Pediatric Heart Transplant, Induction Therapy and Tacrolimus Don't.
Giuliano K; Canner JK; Scully BB; Clarke N; Fraser CD; Ravekes W; Mettler B; Jacobs ML; Sen DG
Ann Thorac Surg; 2022 Nov; 114(5):1794-1802. PubMed ID: 34563503
[TBL] [Abstract][Full Text] [Related]
22. Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk.
Van Besien K; Bachier-Rodriguez L; Satlin M; Brown MA; Gergis U; Guarneri D; Hsu J; Phillips AA; Mayer SA; Singh AD; Soave R; Rossi A; Small CB; Walsh TJ; Rennert H; Shore TB
Leuk Lymphoma; 2019 Jul; 60(7):1693-1696. PubMed ID: 30741059
[TBL] [Abstract][Full Text] [Related]
23. Kidney Transplant Recipients Have Higher Malignancy Prevalence Than Hemodialyzed Patients.
Pyrża M; Małyszko J; Głogowski T; Wieliczko M; Żebrowski P; Małyszko J
Transplant Proc; 2022 May; 54(4):972-975. PubMed ID: 35282885
[TBL] [Abstract][Full Text] [Related]
24. Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation during adulthood and childhood: a registry study.
Francis A; Johnson DW; Teixeira-Pinto A; Craig JC; Wong G
Nephrol Dial Transplant; 2018 May; 33(5):881-889. PubMed ID: 29342279
[TBL] [Abstract][Full Text] [Related]
25. Low 5-year cumulative incidence of post-transplant lymphoproliferative disorders after solid organ transplantation in Switzerland.
Steiner R; Kridel R; Giostra E; McKee T; Achermann R; Mueller N; Manuel O; Dickenmann M; Schuurmans MM; de Leval L; Fehr T; Tinguely M; Binet I; Cogliatti S; Haralamvieva E; Koller M; The Swiss Transplant Cohort Study Stcs ; Dietrich PY
Swiss Med Wkly; 2018; 148():w14596. PubMed ID: 29518251
[TBL] [Abstract][Full Text] [Related]
26. Post-transplant lymphoproliferative disease may be an adverse risk factor for patient survival but not graft loss in kidney transplant recipients.
Francis A; Johnson DW; Craig J; Teixeira-Pinto A; Wong G
Kidney Int; 2018 Oct; 94(4):809-817. PubMed ID: 30173897
[TBL] [Abstract][Full Text] [Related]
27. Posttransplant Lymphoproliferative Disorders in Irish Renal Transplant Recipients: Insights From a National Observational Study.
OʼRegan JA; Prendeville S; McCaughan JA; Traynor C; OʼBrien FJ; Ward FL; OʼDonovan D; Kennedy C; Berzan E; Kinsella S; Williams Y; OʼKelly P; Deady S; Comber H; Leader M; Conlon PJ
Transplantation; 2017 Mar; 101(3):657-663. PubMed ID: 27214265
[TBL] [Abstract][Full Text] [Related]
28. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
Zimmermann H; Nitsche M; Pott C; Reinke P; Babel N; Hermann RM; Hauser IA; Hahn D; Ritgen M; Pietschmann C; Klapper W; Anagnostopoulos I; Trappe RU;
Ann Hematol; 2021 Aug; 100(8):2043-2050. PubMed ID: 33973053
[TBL] [Abstract][Full Text] [Related]
29. Kidney Transplantation Rates Across Glomerulonephritis Subtypes in the United States.
OʼShaughnessy MM; Liu S; Montez-Rath ME; Lafayette RA; Winkelmayer WC
Transplantation; 2017 Oct; 101(10):2636-2647. PubMed ID: 28207635
[TBL] [Abstract][Full Text] [Related]
30. Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients.
Opelz G; Unterrainer C; Süsal C; Döhler B
Nephrol Dial Transplant; 2016 Aug; 31(8):1360-7. PubMed ID: 27190384
[TBL] [Abstract][Full Text] [Related]
31. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
[TBL] [Abstract][Full Text] [Related]
32. Variation in Nonmelanoma Skin Cancer Incidence by Treatment Modality Among Patients Receiving Multiple Kidney Transplants.
Sexton DJ; O'Kelly P; O'Leary E; Murray S; Deady S; Daly F; Egan J; Houlihan DD; McCormick PA; Morris PG; Ni Raghallaigh S; Moloney FJ; O'Neill JP; Conlon PJ
JAMA Dermatol; 2019 May; 155(5):594-598. PubMed ID: 30725084
[TBL] [Abstract][Full Text] [Related]
33. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
[TBL] [Abstract][Full Text] [Related]
34. Short-term decreased post transplant lymphoproliferative disorder risk after kidney transplantation using two novel regimens.
Chiodo Ortiz A; Petrossian G; Addonizio K; Hsiao A; Koizumi N; Yu Y; Plews R; Conti D; Ortiz J
Transpl Immunol; 2023 Feb; 76():101774. PubMed ID: 36528248
[TBL] [Abstract][Full Text] [Related]
35. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States.
Quinlan SC; Pfeiffer RM; Morton LM; Engels EA
Am J Hematol; 2011 Feb; 86(2):206-9. PubMed ID: 21264909
[TBL] [Abstract][Full Text] [Related]
36. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
[TBL] [Abstract][Full Text] [Related]
37. Posttransplantation glomerulonephritis: risk factors associated with kidney allograft loss.
Ostrowska J; Pazik J; Lewandowski Z; Mróz A; Perkowska-Ptasińska A; Durlik M
Transplant Proc; 2007 Nov; 39(9):2751-3. PubMed ID: 18021977
[TBL] [Abstract][Full Text] [Related]
38. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
[TBL] [Abstract][Full Text] [Related]
39. Rituximab for remission induction in recurrent ANCA-associated glomerulonephritis postkidney transplant.
Murakami C; Manoharan P; Carter-Monroe N; Geetha D
Transpl Int; 2013 Dec; 26(12):1225-31. PubMed ID: 24118474
[TBL] [Abstract][Full Text] [Related]
40. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients.
Reams BD; McAdams HP; Howell DN; Steele MP; Davis RD; Palmer SM
Chest; 2003 Oct; 124(4):1242-9. PubMed ID: 14555552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
